Immunocin α, an Immuno-modulator and a brand of Gufic Biosciences for the same drug, will significantly reduce the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19. The medical armamentarium urgently needs many more tools to fight the COVID-19 pandemic, which is a leading cause of mortality and a strain on the social wellbeing and healthcare system all around the world, the press statement highlighted.
Immunocin α Phase 3 Study was a, multi-centric, randomized, placebo-controlled, double-blind study in hospitalized adult patients with laboratory-confirmed moderate-to-severe COVID-19. The primary objective of the study was to assess and compare the efficacy of Thymosin α-1 (Tα1) in combination with Standard of Care Treatment (SOC) versus placebo with SOC.
Gufic Biosciences is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
On a consolidated basis, the company reported a 36% jump in net profit to Rs 21 crore on a 3.3% rise in net sales to Rs 172 crore in Q3 FY22 over Q3 FY21.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.